Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Method and kit for predicting risk of neurodegenerative diseases

A neurodegenerative and reagent kit technology, which is applied in the field of immunological diagnosis and medicine, and can solve problems such as large trauma

Active Publication Date: 2020-10-20
XUANWU HOSPITAL OF CAPITAL UNIV OF MEDICAL SCI
View PDF2 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, the detection of cerebrospinal fluid is a traditional lumbar puncture, which is relatively traumatic and has certain risks

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Method and kit for predicting risk of neurodegenerative diseases
  • Method and kit for predicting risk of neurodegenerative diseases
  • Method and kit for predicting risk of neurodegenerative diseases

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0087] Embodiment 1: data set and statistical method

[0088] 1.1 Research Datasets

[0089] A total of 4 datasets were included in this study ( figure 1 A): Discovery cohort, validation cohort, asymptomatic AD study cohort and AD family study cohort.

[0090] In the discovery cohort, subjects were recruited from Beijing area (n=82 cases, including 28 cases of AD patients, 25 cases of MCI patients, and 29 cases of healthy control group).

[0091] In the validation cohort, subjects were recruited from Shandong, Guizhou, Henan, Hebei, Jilin, Guangxi and Inner Mongolia Autonomous Region (n=216 cases, including 73 AD patients, 71 MCI patients, and 72 healthy controls) .

[0092] In the asymptomatic AD research cohort, 320 subjects were recruited from 2012 to 2014, including 160 normal controls and 160 asymptomatic AD subjects. These subjects were all cognitively normal at the baseline, and blood was collected, and their cerebrospinal fluid markers and cognitive function cha...

Embodiment 2

[0097] Example 2: Collection and detection of peripheral blood neuron-derived exosomes

[0098] 2.1 Collection of exosomes

[0099] Collect 20 ml of fasting (12-hour fasting) venous blood from all subjects in the morning, and use polypropylene tubes containing ethylenediaminetetraacetic acid (EDTA) for collection tubes. To obtain neuron-derived exosomes, whole blood samples were processed in the central laboratory of Xuanwu Hospital, Capital Medical University. For blood samples collected in areas other than Beijing, the samples should be centrifuged at 4200×g for 10 minutes at room temperature to obtain plasma, then stored at 4°C, stored on dry ice and transported to the central laboratory of Xuanwu Hospital within 12 hours. In the discovery cohort (dataset 1) and the validation cohort (dataset 2), blood samples were processed immediately upon arrival at the central laboratory, and specific neuron-derived exosomes were isolated according to published protocols (see Jia L ...

Embodiment 3

[0108] Example 3: Correlation between exosomal synaptic proteins and cerebrospinal fluid synaptic proteins

[0109] In order to verify whether GAP43, neurograin, SNAP25 and synaptotagmin 1 in neuron-derived exosomes could be used as candidate markers for AD diagnosis, we conducted a comparison between exosomal synapsin and CSF synapsin correlation analysis. In the discovery cohort, we found that blood exosome levels of GAS43, neurogranulin, SNAP25, and synaptotagmin 1 were significantly inversely correlated with CSF levels ( Figure 6 ): GAP43 of AD group, R 2 =0.65, P Figure 6 A; GAP43 in MCI group, R 2 =0.70, P Figure 6 B; GAP43 in the control group, R 2 =0.67, P Figure 6 C; Neurogranulin in AD group, R 2 =0.58, P Figure 6 D; Neurogranulin in MCI group, R 2 =0.54, P Figure 6 E; Neurogranulin in the control group, R 2 =0.57, P Figure 6 F; SNAP25 in AD group, R 2 =0.63, P Figure 6 G; SNAP25 R in the MCI group 2 =0.64, P Figure 6 H; SNAP25 in the control group, R 2 =...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a method and a kit for predicting the risk of neurodegenerative diseases. According to the method, based on the level of biomarkers in a biological sample, the risk of neurodegenerative diseases in subjects is predicted, wherein the biomarkers are growth-related protein 43 (GAP43), neurogranin, synaptosome-associated protein 25 (SNAP25), and synaptotagmin 1. The method disclosed by the invention can be used for detecting the AD in an asymptomatic period, even can be used for predicting the AD suffering risk of a subject 5-7 years before onset of the AD, and has the advantages of almost no wound, low risk and the like.

Description

technical field [0001] The present application relates to the field of medicine, virology and immunology, especially the field of immunological diagnosis. Specifically, the present application discloses a method for predicting the risk of a neurodegenerative disease in a subject, which includes: (1) obtaining a biological sample containing a biomarker from the subject; (2) measuring the biological sample and (3) predicting the risk of a neurodegenerative disease in a subject based on the level of the biomarker; wherein the biomarker is GAP43, neurogranulin, SNAP25, and synaptotagmin 1 ; and a kit for use in said method. In addition, the application also discloses the use of the kit for predicting the risk of neurodegenerative diseases in subjects. Background technique [0002] Alzheimer's disease (AD) currently lacks effective therapeutic drugs and requires early intervention. But the difficulty of early intervention lies in the early diagnosis of AD, especially the diagn...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): G01N33/68G01N33/543C12Q1/6883
CPCC12Q1/6883C12Q2600/158G01N33/54306G01N33/6896G01N2800/2814G01N2800/2821G01N2800/60
Inventor 贾建平贾龙飞杨坚炜朱敏
Owner XUANWU HOSPITAL OF CAPITAL UNIV OF MEDICAL SCI
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com